Abstract
Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction, and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically. These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition.
Keywords: Chronic prostatitis, chronic pelvic pain syndrome, irritative voiding, sexual dysfunction, pelvic pain, pharmacological interventions.
Current Pharmaceutical Design
Title:Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
Volume: 27 Issue: 25
Author(s): Nasrin Aktar, Ahmed Moudud, Tingting Chen, Xiaoqing Gao, Hanhui Min, Meng Tang and Xiaohui Zhou*
Affiliation:
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198,China
Keywords: Chronic prostatitis, chronic pelvic pain syndrome, irritative voiding, sexual dysfunction, pelvic pain, pharmacological interventions.
Abstract: Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction, and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically. These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition.
Export Options
About this article
Cite this article as:
Aktar Nasrin, Moudud Ahmed, Chen Tingting , Gao Xiaoqing , Min Hanhui , Tang Meng and Zhou Xiaohui *, Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome, Current Pharmaceutical Design 2021; 27 (25) . https://dx.doi.org/10.2174/1381612827666210322125054
DOI https://dx.doi.org/10.2174/1381612827666210322125054 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Antioxidant, Anticancer and Antiviral Activities of Novel Quinoxaline Hydrazone Derivatives and their Acyclic C-Nucleosides
Medicinal Chemistry New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Accelerator Production of Scandium Radioisotopes: Sc-43, Sc-44, and Sc-47
Current Radiopharmaceuticals Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry Combating Diseases with Computational Strategies Used for Drug Design and Discovery
Current Topics in Medicinal Chemistry Theranostics of Metastatic Prostate Cancer Applying <sup>64</sup>Cu/<sup>18</sup>F/<sup>68</sup>Ga PSMA PET-CT and <sup>177</sup>Lu Radiopharmaceuticals
Current Radiopharmaceuticals Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Synthesis of 1,3,2-Benzodiazaphosphorine and 1,3,2-Benzodiazaphosphorine- 2-sulfide
Letters in Organic Chemistry NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry Imaging Malignant Gliomas with 99mTc-MIBI Brain Single-Photon Emission Computed Tomography
Current Medical Imaging Potential Health Hazards for Cumulative Exposures to Phthalates and Ionizing Radiation in High-Risk Pediatric Population
Mini-Reviews in Medicinal Chemistry Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Antioxidant Effect of Mangiferin and its Potential to be a Cancer Chemoprevention Agent
Letters in Drug Design & Discovery Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease
Current Molecular Pharmacology Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design